Changes in cellular virus load and zidovudine resistance of syncytium- inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: A clonal analysis

Journal of Infectious Diseases

Volumn 174, Issue 4, 1996, Pages 845-849

  Van't Wout, Angélique B ^c   De Jong, Menno D ^c   Kootstra, Neeltje A ^c   Veenstra, Jan ^c   Lange, Joep M A ^c   Boucher, Charles A B ^b   Schuitemaker, Hanneke ^a  

^a CENTRAL LABORATORY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ARTICLE; CLONAL ANERGY; CODON; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHENOTYPE; PRIORITY JOURNAL; SYNCYTIUM; T LYMPHOCYTE SUBPOPULATION; VIRUS ISOLATION; VIRUS MUTANT;

EID: 19244364789     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.4.845     Document Type: Article

References (15)

1. Schuitemaker H, Koot M, Kootstra NA, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J Virol 1992;66:1354-60.
2. Koot M, Van 't Wout AB, Kootstra NA, De Goede REY, Tersmette M, Schuitemaker H. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J Infect Dis 1996;173:349-54.
3. + cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-8.
4. Koot M, Schellekens PThA, Mulder JW, et al. Viral phenotype and T-cell reactivity in human immunodeficiency virus type 1 -infected asymptomatic men treated with zidovudine. J Infect Dis 1993;168:733-6.
5. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995;122:401-8.
6. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-8.
7. Kellam P, Boucher CAB, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of Kigh-level resistance to zidovudine. Proc Natl Acad Sci USA 1992;89:1934-8.
8. Mohri H, Singh MK, Ching WTW, Ho DD. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc Natl Acad Sci USA 1993;90:25-9.
9. Boucher CAB, Lange JMA, Miedema F, et al. HIV-1 biological phenotype and development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992;6:1259-64.
10. Larder BA, Boucher CAB. PCR detection of human immunodeficiency virus drug resistance mutations. In: Persing DH, Smith TF, Tenover FC, White TJ, eds. Diagnostic molecular microbiology, principles and applications. Washington, DC: American Society for Microbiology, 1993:527-33.
11. Schuurman R, Van Leeuwen R, Nijhuis M, Kwok S, De Jong D, Boucher CAB. Turnover of syncytium inducing and non-syncytium inducing HIV-1 in patients treated with 3TC (abstract). J Acquir Immune Defic Syndr 1995;10(suppl 3).
12. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-9.
13. De Jong MD, Veenstra J, Stilianakis NI, et al. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of HIV-1 RNA load suppression by zidovudine. Proc Natl Acad Sci USA 1996;93:550-6.
14. Gao WY, Agbaria R, Driscoll JS, Mitsuya H. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994;269:12633-8.
15. + T cell decline in vivo. Virology 1996;219:87-95.